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SYNOPSIS 
Adalimumab is clinically effective for treating non-infectious posterior segment uveitis. Its cost-
effectiveness is uncertain due to scarcity of evidence but appears to be more cost-effective in patients 
with active uveitis at high risk of blindness.  
ABSTRACT  
Background/Aims 
Uveitis is inflammation inside the eye. Our objective was to assess the cost-effectiveness of adalimumab 
compared with current practice (immunosuppressants and systemic corticosteroids) in patients with 
non-infectious intermediate, posterior or panuveitis and to identify areas for future research.  
Methods 
A Markov model was built to estimate costs and benefits of the interventions. Systematic reviews were 
performed to identify the available relevant clinical and cost-effectiveness evidence. Data collected in 
two key randomised controlled trials (VISUAL I and VISUAL II) were used to estimate the 
LQWHUYHQWLRQV¶ effectiveness compared with the WULDOV¶ comparator arms (placebo plus limited current 
practice (LCP)). The analysis was performed from the National Health Service (NHS) and Personal 
Social Services perspective. Costs were calculated based on standard UK sources.  
Results 
The estimated incremental cost-effectiveness ratios (ICERs) of adalimumab versus LCP for the base 
case are £92,600 and £318,075 per quality-adjusted life year (QALY) gained for active and inactive 
uveitis respectively. In sensitivity analyses, the ICER varied from £15,579 to £120,653 and £35,642 to 
£800,775 per QALY for active and inactive uveitis.  
Conclusion 
The estimated ICERs of adalimumab versus LCP are above generally accepted thresholds for cost-
effectiveness in the UK. Adalimumab may be more cost-effective in patients with active uveitis at 
greater risk of blindness. However, there is an unmet need for additional primary data to provide more 
reliable estimates in several important areas, including: effectiveness of adalimumab versus current 
practice (instead of LCP); incidence of long term blindness; adalimumab effectiveness in avoiding 
blindness; and, rates and time to remission whilst on adalimumab.  
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INTRODUCTION 
Uveitis describes a group of conditions characterised by inflammation inside the eye whose underlying 
cause may be broadly divided into infectious and non-infectious. In developed countries the cause is 
most commonly non-infectious, and appears to be autoimmune in origin, either idiopathic or associated 
with a systemic autoimmune disorder. The blindness causing forms of non-infectious uveitis are those 
that affect the posterior structures of the eye, namely intermediate uveitis, posterior uveitis and 
panuveitis. Consequences of uveitis, which may lead to vision loss, include early complications such 
as cystoid macular oedema and vitreous haze, and late complications such as cataracts, glaucoma, and 
irreversible damage to the retina. It has been estimated that uveitis accounts for 10% to 15% of all cases 
of total blindness in the United States, [1] and between three and ten out of 100,000 people in the 
European Union are estimated to have non-infectious posterior segment uveitis.[2]  
Treatment for non-infectious uveitis depends upon whether systemic disease exists (and if so, whether 
it is controlled), and whether the inflammation affects one or both eyes. Initially, it is usually treated 
administering corticosteroids, systemically or locally via periocular or intravitreal injections or 
intravitreal implants. Systemic corticosteroids carry significant morbidity (e.g. cataract, glaucoma, 
diabetes, and osteoporosis) and long-term use is not recommended. Therefore, people with severe or 
chronic non-infectious uveitis, whose disease has not adequately responded to corticosteroids, for whom 
corticosteroids are not appropriate, or whose uveitis recurs after tapering the corticosteroid dose, may 
be given immunosuppressive drugs (such as methotrexate, mycophenolate mofetil, and cyclosporine) 
as second line treatment. Immunosuppressive drugs can allow a reduction in the corticosteroid dose and 
associated complications. If the disease is still active or if these treatments are not tolerated, especially 
in patients at high risk of losing their vision or those with systemic disease related to uveitis, biologics 
such as adalimumab (Humira®) may be used. However, healthcare providers need to know whether 
these treatments are cost-effective compared with usual care to inform recommendations about their 
use in practice. The objective of our study is to assess the cost-effectiveness of adalimumab compared 
with current practice (immunosuppressants and systemic corticosteroids) in patients with non-infectious 
intermediate, posterior or panuveitis and to identify areas for future research.  
 
METHODS 
Systematic reviews (described elsewhere [3]) were undertaken to assess the clinical effectiveness and 
safety of adalimumab and to identify the evidence relevant to our economic evaluation. Two 
randomised controlled trials were identified in the clinical effectiveness review that reported outcomes 
for adalimumab in the target population: VISUAL I [4] and VISUAL II,[5] which recruited patients 
with active and inactive non-infectious uveitis, respectively (see Table 1 for a summary of these trials¶
characteristics). These trials provided most of the outcomes used in the model. The use of a network 
meta-analysis (NMA) was explored to compare the effectiveness of treatments. Unfortunately, it was 
considered infeasible and inappropriate to conduct an NMA because the systematic review did not 
identify any sources of evidence for the target population that reported comparable effectiveness 
measures that formed a connected network of evidence. 
 
Table 1: Summary of study characteristics of VISUAL I and VISUAL II  
 VISUAL I [4] VISUAL II [5] 
Population (n) 223 229 
  Age (mean) 42.7 years 42.5 years 
  % of females 57% 62% 
Type of uveitis Active Inactive 
  % of bilateral 91% 96% 
Intervention Adalimumab (40 mg dose every other 
week) 
Adalimumab (40 mg dose every other 
week) 
Comparator Placebo Placebo 
Concomitant treatments 
(% of patients) 
Oral prednisone 60 mg/d tapered 
to 0 mg by week 15 (100%) 
Immunosuppresant (32%*) 
Oral prednisone 10 to 35mg/d 
tapered to 0 mg by week 19 or 
earlier (100%) 
Immunosuppresant (47%*) 
Primary outcome Time to treatment failure Time to treatment failure 
Secondary outcomes BCVA, change in VH or AC grade, % 
change in CRT, time to MO, change 
in VFQ-25, adverse events 
BCVA, change in VH or AC grade, % 
change in CRT, time to MO, change in 
VFQ-25, adverse events 
*Balanced across both arms. AC, anterior chamber; BCVA: best-corrected visual acuity; CRT, central retinal thickness; 
MO, macular oedema; VFQ, Visual Functioning Questionnaire;  VH, vitreous haze 
 
Model design 
To estimate and analyse the cost effectiveness of adalimumab for non-infectious uveitis, compared with 
current practice, we built a Markov model. The model simulates a cohort of patients, which is followed 
over a lifetime. The analysis is performed from a National Health Service (NHS) and Personal Social 
Services (PSS) perspective. Costs and quality-adjusted life years (QALYs) are discounted at a rate of 
3.5% per year. The modelled population consists of people with active or inactive non-infectious 
intermediate, posterior or pan uveitis, with more than 90% having bilateral uveitis. A corticosteroid 
burst was given to all patients at the start of VISUAL I whilst patients in VISUAL II were already 
receiving high-dose corticosteroids at randomisation. Corticosteroids were tapered to zero by week 15 
in VISUAL I and week 19 in VISUAL II. Given the evidence available, the intervention considered in 
the analysis is a subcutaneous injection of 40mg of adalimumab every two weeks plus an initial oral 
corticosteroid burst (instead of adalimumab alone) whilst the comparator is current practice, which 
includes corticosteroids and a range of immunosuppressants (such as methotrexate, mycophenolate 
mofetil, and cyclosporine). Current practice is assumed to be equivalent to the control arm (placebo) in 
VISUAL I and VISUAL II, in which 32% of patients were receiving at least one immunosuppressant 
at baseline (across arms). Given that a greater proportion of patients in current practice are likely to 
receive immunosuppressants, the comparator is denoted throughout as limited current practice (LCP).  
The model structure, presented in  
Figure 1, includes five health states: (i) on treatment; (ii) post treatment failure; (iii) blindness; (iv) 
remission; and, (v) death. Patients VWDUWLQWKH³RQWUHDWPHQW´VWDWHDQGPD\discontinue treatment due 
to either treatment failure as defined in the VISUAL I and II trials[4, 5], in which case they transition 
WR³SRVWWUHDWPHQWIDLOXUH´, or after two years on treatment, due to achieving remission, in which case 
they transition to the ³UHPLVVLRQ´ state. Patients iQ WKH ³SRVW WUHDWPHQW IDLOXUH´ state are at risk of 
experiencing permanent damage to the eye and PD\WUDQVLWLRQWR³EOLQGQHVV´Upon entering remission, 
patients do not receive further adalimumab treatment but they maintain the benefit of the previous 
treatment. Given the lack of data, the probability of remission was assumed to be zero in the base case 
and its impact explored in sensitivity analyses. Patients can transition to the ³GHDWK´VWDWHDWDQ\WLPH. 
Treatment benefit is represented by higher health-related quality of life (HRQoL) and lower rates of 
adverse events and treatment failure, resulting in turn in a reduced risk of permanent blindness. For 
more details on the model, please refer to the corresponding HTA report.[3] 
 
Figure 1:  State transition diagram of the decision model  
 [INTRODUCE FIGURE 1 HERE] 
 
Model inputs 
Model input parameters were taken from a variety of sources. A summary of these parameters are 
included in Table 2. 
Utilities 
EQ-5D scores, where one is equivalent to full health and zero is equivalent to death, were used in the 
analysis to derive utility values representing HRQoL. For each treatment arm, average EQ-5D scores 
measured at each time point in the relevant arms of VISUAL I and VISUAL II were used. These scores 
were taken from confidential Clinical Study Reports of the respective trials and therefore are not 
included in Table 2. 3DWLHQWVLQWKH³SRVWWUHDWPHQWIDLOXUH´ state were assigned the average EQ-5D at 
baseline whilst patients in remission were assigned the average EQ-5D score measured at the end of the 
9,68$/ , WULDO )RU WKH ³EOLQGQHVV´ VWDWH ZH FRQVLGHUHG two studies of utilities associated with 
blindness based in the UK: Czoski-Murray et al.,[6] which led to an estimated EQ-5D score of 0.38, 
and Brown,[7] who reports a score of 0.57. Both estimates were used in sensitivity analyses. 
Treatment failure 
Treatment failure was defined in the VISUAL I and II trials[4, 5] as fulfilling at least one of these four 
criteria: (i) development of new inflammatory lesions; (ii) worsening of anterior chamber cell grade; 
(iii) worsening of vitreous haze grade; or (iv) worsening of visual acuity. Time to treatment failure was 
modelled using parametric survival functions fitted to Kaplan-Meier survival functions from the trials. 
Amongst the parametric survival functions fitted, the log normal was deemed the most appropriate in 
terms of statistical goodness-of-fit and clinical plausibility. After treatment failure, patients were 
assumed to continue on LCP.  
Permanent blindness 
The VISUAL I and II trials did not report any occurrence of permanent blindness, probably because of 
their short duration [4, 5, 8]. However, we assume that adalimumab, by preventing permanent damage 
to the eye, could prevent future blindness. We identified three relevant sources to estimate the blindness 
rate associated with current practice: Dick et al.,[9] a retrospective analysis of insurance claims data of 
patients with posterior segment, non-infectious uveitis; Tomkins-Netzer et al.,[10] which included a 
wider population than our target population (including patients with infectious and anterior uveitis); 
and, Durrani et al.,[11] based on a tertiary referral centre. Dick et al. was used in the base case analysis, 
as it was deemed the most appropriate source because of its large sample size (n=1769) and because it 
only included patients with posterior segment non-infectious uveitis; Tomkins-Netzer et al. and Durrani 
et al. were used in sensitivity analyses. We assumed that patients could not go blind before treatment 
failure.  
Adverse events 
Given that EQ-5D data were used to model treatment effectiveness, the impact on quality of life 
associated with adverse events (AEs) was already captured. Only the additional costs associated with 
the AEs whose treatment cost is substantial were modelled: cataract, raised intraocular pressure, 
glaucoma, serious infections, hypertension, fractures, and diabetes. The probabilities for AEs per cycle 
were calculated based on the incidence in the trials. 
Costs 
We included treatment costs, administration costs and monitoring costs as well as adverse event costs 
and the cost of permanent blindness. Adalimumab is assumed to be mostly self-administered with only 
10% of patients needing help from a district nurse. We assumed that patients would receive monitoring 
every six weeks irrespective of treatment, consisting of outpatient visits to assess the efficacy of the 
treatments and to monitor the risk of AEs. It is also assumed that patients receiving immunosuppressants 
would receive six additional blood monitoring visits annually. The costs of treatment for AEs were on 
NHS Reference Costs 2014-15,[12] except raised intraocular pressure, which was assumed to be treated 
with two doses of bimatoprost, and the treatment for hypertension, which was based on Breeze et al.[13] 
The cost of blindness, which includes NHS costs as well as PSS costs, was based on the cost estimated 
by Colquitt et al.[14] for age-related macular degeneration and was updated with the most recent cost 
data. 
Table 2: Model input parameters for the base case analysis 
Parameters Mean Distribution 
used in PSA  
Source 
Starting age (active/inactive) 42.7/42.5 Fixed VISUAL I/VISUAL II[4, 5] 
Discount rate (costs and utilities) 3.5% Fixed NICE Reference Case[15] 
Gender (% males) 43%/39% Fixed VISUAL I/VISUAL II[4, 5] 
Cycle length 2 weeks Fixed  
Utilities    
Baseline EQ-5D (active/inactive) 0.83/0.85 Beta VISUAL I/VISUAL II[4, 5] 
EQ-5D at different time points Confidential Beta VISUAL I/VISUAL II* 
Blindness utility 0.38 Multivariate 
normal  
Czoski-Murray et al.[6] 
Proportion of bilateral uveitis 
(active/inactive) 
90.8/95.6% Beta VISUAL I/VISUAL II[4, 5] 
Probability of blindness (annual) 0.0068 Beta Dick et al.[9] 
Drug costs    
Adalimumab 40mg £352.14 Fixed BNF[16] 
Prednisolone £1.24 Fixed BNF[16] 
Mycophenolate mophetil £9.31 Fixed BNF[16] 
Methotrexate £2.40 Fixed BNF[16] 
Cyclosporine £48.50 Fixed BNF[16] 
Azathioprine £3.24 Fixed BNF[16] 
Bimatoprost £11.71 Fixed BNF[16] 
Adcal D3 £7.49 Fixed BNF[16] 
Omeprazole £1.17 Fixed BNF[16] 
Administration and monitoring  
Monitoring visit frequency 6 weeks  Jabs et al.[17] 
Monitoring visit cost £96.11 Gamma  NHS Reference costs 2014-15[12] 
% of patients needing nurse help 
for adalimumab injection 
10% Beta NICE TA375[18] 
Adalimumab administration help 
cost 
£44 Gamma PSSRU 2015[19] 
Costs of adverse events    
Cataract surgery £852.40 Gamma NHS Reference costs 2014-15[12] 
Raised intraocular pressure £23.42 Gamma BNF[16] 
Glaucoma procedure £581.25 Gamma NHS Reference costs 2014-15[12] 
Serious infection £5,940.50 Gamma  NHS Reference costs 2014-
15[12], VISUAL I and II 
Hypertension £7.04 Gamma Breeze et al.[13] 
Parameters Mean Distribution 
used in PSA  
Source 
Blindness (onset) £237 Gamma Colquitt et al.[14] 
Blindness (annual) £7,659 Gamma Colquitt et al.[14] 
Fracture £2,116.17-
£6,022.62 
Gamma Davis et al.[20] 
Diabetes £1,521.46 Gamma Alva et al.[21], Breeze et al.[13] 
*From the confidential Clinical Study Report of VISUAL I and VISUAL II. 
BNF: British National Formulary; NHS: National Health Service; NICE: National Institute for Health 
and Care Excellence; PSA: probabilistic sensitivity analysis; PSSRU: Personal Social Services Research 
Unit; TA: Technology Assessment. 
 
Model analysis 
We estimated the incremental cost-effectiveness ratios (ICERs), in terms of incremental cost (in pounds 
sterling) per QALY gained, of adalimumab plus LCP compared with LCP, in patients with active and 
inactive uveitis. For the base case analysis we ran probabilistic sensitivity analyses (PSA) by specifying 
input parameters as probability distributions and propagating the uncertainty through the model using 
Monte Carlo simulation (5,000 samples), hence allowing for non-linearity and producing an estimate 
of the decision uncertainty. Given the scarcity of relevant evidence on key model parameters, we 
supplemented the base case analysis with a range of exploratory analyses using alternative evidence 
sources and assumptions. In one such exploratory analysis, we used evidence from the Multicenter 
Uveitis Steroid Treatment (MUST) trial,[22] where fluocinolone corticosteroid implant was compared 
with systemic corticosteroids and immunosuppressants, the primary outcome being change in best-
corrected visual acuity (BCVA), in patients with active non-infectious posterior segment uveitis. In the 
MUST trial, a greater proportion of patients in the comparator arm were treated with a mix of systemic 
steroids and immunosuppressant (86%), which reflects current practice better. We also conducted 
exploratory analyses combining different blindness rates and utility estimates associated with blindness, 
based on alternative sources, as well as alternative remission rates. Finally, we conducted exploratory 
analyses using alternative parametric survival functions (Weibull and Gompertz distributions) to the 
log normal distribution used in the base case to extrapolate time to treatment. 
RESULTS 
Base case analysis 
In patients with active uveitis, adalimumab in combination with LCP was estimated to produce 0.200 
incremental QALYs compared with LCP alone at an additional cost of £18,541, resulting in an ICER 
of £92,600 per QALY gained as shown in Table 3. The ICER generated using the deterministic version 
of the model (£94,262) was similar to that from the probabilistic model. In patients with inactive uveitis, 
adalimumab plus LCP was estimated to produce 0.119 incremental QALYs compared with LCP alone 
at an extra cost of £37,784, resulting in an ICER of £318,075 per QALY gained. 
Table 3: Results of the base case analysis comparing adalimumab + LCP(VI) vs 
LCP(VI) in patients with active uveitis and adalimumab + LCP(VII) vs LCP(VII) in 
patients with inactive uveitis (probabilistic) 
 Total 
QALYs 
Total 
costs 
Inc. 
QALYs 
Inc. 
costs 
ICER Probability of 
cost-effectiveness 
at WTP threshold 
£20,000 £30,000 
Active uveitis 
LCP(VI) 15.221 £49,036       1.00 1.00 
Adalimumab + 
LCP(VI) 
15.421 £67,577 0.200 £18,541 £92,600 0.00 0.00 
Inactive uveitis 
LCP(VII) 15.549 £50,230       1.00 1.00 
Adalimumab + 
LCP(VII)* 
15.668 £88,014 0.119 £37,784 £318,075 0.00 0.00 
*LCP(VI)= Limited current practice, as provided in the VISUAL I trial: initial systemic steroid burst tapered 
by week 15 and around 30% of patients on systemic immunosuppressants; LCP(VII)= Limited current 
practice, as provided in the VISUAL II trial: on systemic steroids at baseline tapered by week 19 and around 
47% of patients on systemic immunosuppressants; WTP: willingness to pay. 
 
Sensitivity analyses 
In the exploratory analysis we conducted based on the MUST trial, the ICER for adalimumab versus 
current practice in patients with active uveitis is £110,068 per QALY compared with £94,262 per QALY 
in the base case. The results of  the exploratory analyses combining different blindness rates and utilities 
are shown in Table 4. In patients with active uveitis, the ICER for adalimumab versus LCP using the 
blindness rate from Durrani et al.[11] is reduced from the base case £94,262 to £32,544 per QALY but 
increases to £120,650 per QALY using the lower blindness rate based on Tomkins-Netzer et al.[10] 
Using the utility estimates associated with blindness reported by Brown[7] instead of Czoski-Murray et 
al.,[6] the ICER for adalimumab versus LCP increased to £117,571 per QALY. Assuming that after 
two years of successful treatment, some patients would achieve remission and no longer require 
adalimumab, led to a considerable reduction of the ICER for adalimumab versus LCP: in patients with 
active uveitis; it decreased to £66,176 and £55,161 per QALY assuming annual remission rates of 0.1 
and 0.2 respectively. The lowest estimated ICER for adalimumab versus LCP is £15,579 per QALY 
when using the utility score for blindness from Czoski-Murray et al.,[6] the blindness rate calculated 
from Durrani et al.[11] and assuming an annual remission rate of 0.2 after the second year of successful 
treatment. Exploratory analyses using alternative parametric survival functions to extrapolate time to 
treatment failure showed that the ICER for adalimumab versus LCP was slightly higher when using a 
Gompertz distribution (£100,225 per QALY) and a Weibull distribution (£102,218 per QALY) 
compared with the log normal distribution used in the base case.  
Table 4: Exploratory analyses using different sources for the rate of blindness, utility score for 
blindness and different rates of remission after two years in patients with active uveitis. 
(deterministic) 
Blindness utility Czoski-Murray[6]  Brown[7] 
Remission rate 0*  0.1 0.2 0 0.1 0.2 
Blindness rate       
Tomkins-Netzer et al. 
[10] £120,650 £85,785 £72,111 £141,099 £100,324 £84,332 
Dick et al. [9]* £94,262* £66,176 £55,161 £117,571 £82,540 £68,801 
Durrani et al. [11] £32,544 £20,358 £15,579 £48,094 £30,086 £23,024 
*base case 
 
The same sensitivity analyses were undertaken for inactive patients (except from the analysis based on 
the MUST trial, given that it only included active patients) and all analyses resulted in an ICER greater 
than £35,000 per QALY gained. 
DISCUSSION 
Adalimumab combined with LCP has shown significant benefit over placebo combined with LCP in 
patients with active and inactive non-infectious posterior segment uveitis.  
Adalimumab has been shown to be clinically effective for treating non-infectious uveitis. We have 
conducted a cost-effectiveness analysis of adalimumab in patients with non-infectious posterior 
segment uveitis from the NHS and PSS perspective. However, the estimated ICERs for adalimumab 
versus LCP in most of our analyses are above the range of £20,000 to £30,000 per QALY gained that 
the National Institute for Health and Care Excellence (NICE) considers as a cost-effective use of NHS 
resources. [15]  Our analyses suggest that it is more cost-effective in patients with active uveitis at 
greater risk of blindness, but that it is unlikely to be considered cost-effective for most patients with 
inactive uveitis from a healthcare SURYLGHU¶V perspective. We recognise however that there is very 
significant uncertainty in these estimates as highlighted by our sensitivity analyses. In addition, this 
perspective does not consider a number of indirect costs and outcomes (such as productivity losses of 
patients and/or carers) and.  
Our analyses, alongside other evidence, informed the decision of where adalimumab should sit within 
the treatment pathway for adults with non-infectious posterior segment uveitis. Within the United 
Kingdom (UK), until recently it was only available on a named patient basis through exceptional 
funding routes dependent on local decision-makers. In this context it was usually used only after 
at least two, and often many more, standard immunosuppressants. From 2017 onwards, expert 
review by NHS England,[23] publication of the VISUAL trials[4, 5] and assessment by 
NICE[24] has resulted in adalimumab becoming a standard part of treatment pathways in the 
UK, being used LQUHIUDFWRU\GLVHDVHDFFRUGLQJWRFULWHULDZKLFKLQFOXGHVµLQDGHTXDWHUHVSRQVH
to VWHURLGV¶DQGµLQDGHTXDWHUHVSRQVHRULQWROHUDQFHWRLPPXQRVXSSUHVVDQWV¶Its place in this 
stage of the pathway aligns with its relatively high cost compared to standard second-line 
immunosuppressants; however, it could be argued that the VISUAL trials provide more robust 
clinical effectiveness and safety data for adalimumab than is currently available for any other 
non-corticosteroid therapy, and that if cost were not a factor it could be used earlier in the 
treatment pathway.  
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